Montreal, 13 June 2016 – According to the partnership between Desjardins – Innovatech and the healthcare technologies campus (CTS Santé) aiming to sustain the creation of promising companies within the medical technologies sector, a 500 000 $ investment is consent by Desjardins – Innovatech to THORASYS Thoracic Medical Systems Inc. (Thorasys) therewith to increase the TremoFlo C-100 commercialization, a lung function diagnosis tool.
Sébastien Jutras, Thorasys Vice-President Operation, : « CTS Health was a key player in the success of our financing round. The extensive expertise of CTS in supporting marketing of medical devices is reflected at all levels of the organization, the direction to the board. We are proud to form this partnership with them to the international expansion of Thorasys. »
Guillaume Hervé, CTS Santé Executive Board President, highlight the strong potential of Thorasys: « With Thorasys we selected a project that emphasize the innovation that profit to the patient and the healthcare personnel. The strong business model is supported by experimented and dynamics entrepreneurs. In this way, we bring all our ressources together in order to achieve sales target as soon as possible.
The TremoFlo C-100 was created after an important research & development phase. Its offers a unique sensibility measure, with fast detection, against pulmonary illnesses, without patient effort. This innovation connects performance and workability with a modern design. The diagnosis improvement of the lung function is the main objective for the 4 creators. According to them, in the actuals practices there is a lack of innovation and they are hard to use, for both healthcare specialists and patients. Therefore Thorasys wants to boost those tools and make the experience more pleasant for the patient.
Desjardins – Innovatech, through the CTS, allows the company to take another important step thanks to the 500 000 $ investment. Indeed, this collaboration gives to Thorasys the means to develop its commercialization, notably with a sales force implementation to promote the TremoFlo C-100 in order to invest the international market. This collaboration between CTS and Desjardins – Innovatech attested the value of the medical technologic innovation and entrepreneurship in Quebec.
THORASYS Thoracic Medical Systems Inc. is a young respiratory medical device company based in Montreal, Quebec, Canada. We apply cutting edge research and technology to the development of products for the diagnosis and monitoring of lung diseases such as Asthma and COPD using the Forced Oscillation Technique (FOT).
TremoFlo™ C-100 Airwave Oscillometry System (AOS) ™ is a compact, portable medical device that permits effortless assessment of lung function in a wide range of patients, including young children and elderly patients.
About CTS Santé:
Since its inception the CTS mission and vision remain the same, to stimulate the momentum of the medical devices sector and actively participate in Quebec’s regional development dynamics in the areas of healthcare technologies.
Its mission is to ensure the development and sustainable growth of promising enterprises in the medical technologies sector and to enhance their national and international exposure.
Desjardins Business Capital régional et coopératif is the venture capital fund management arm of the Mouvement des caisses Desjardins. It manages the assets of Capital régional et coopératif Desjardins, Desjardins-Innovatech SEC and Capital croissance PME.
More than a financial partner, Desjardins Business Capital régional et coopératif makes its network and expertise available for businesses in their growth and expansion, as well as their plans for mergers, acquisitions or public offerings. Nearly 300 companies are already associated with Desjardins Business Capital régional et coopératif.
With more than 35 years of experience in venture capital, Desjardins Business Capital régional et coopératif completes the traditional financing offer in Desjardins Business Centres and is present in all regions of Quebec.
514-384-8555, poste 133
Contact CTS Santé:
Romain Lortille Bruel
Directeur du développement des affaires
Business Development Director
Mobile : 514 808-9775
Tel : 514 274-1001
Contact Desjardins – Innovatech:
418 835-8444 ou 1 866 835-8444, poste 3163